Skip to main content
. 2021 Oct 14;18:72. doi: 10.1186/s12981-021-00387-3

Table 2.

Demographic and clinical characteristics of study participants at baseline

Variablea Clinic A (n = 71) Clinic B (n = 176) Total (N = 247) p-value
Age (years), mean ± SD 48.4 ± 8.4 45.9 ± 8.7 46.7 ± 8.6 0.051
Sex, male 18 (25.4) 41 (23.3) 59 (23.9) 0.865
Comorbidity
 DM only 0 (0) 4 (2.3) 4 (1.6)
 HTN only 63 (88.7) 158 (89.8) 221 (89.5)
 DM and HTN 8 (11.3) 14 (7.9) 22 (8.9) 0.326
Time with NCD (years)
 0–5 43 (60.6) 124 (70.5) 167 (67.6)
 6–10 20 (28.2) 4 (2.3) 24 (9.7)
 > 10 3 (4.2) 3 (1.7) 6 (2.4)  < 0.001
 Missing 5 (7.0) 45 (25.6) 50 (20.2)
Time with HIV (years)
 0–5 31 (43.7) 91 (51.7) 122 (49.4)
 6–10 28 (39.4) 49 (27.8) 77 (31.7)
 > 10 11 (15.5) 15 (8.5) 26 (10.5)
 Missing 1 (1.4) 21 (11.9) 22 (8.9) 0.113
Time on ART (years)
 0–5 48 (67.6) 139 (78.9) 187 (75.7)
 6–10 22 (30.9) 36 (20.5) 58 (23.5)
 > 10 1 (1.1) 1 (0.6) 2 (0.8) 0.155
WHO stage at HIV diagnosis
 0 14 (19.7) 60 (34.1) 74 (29.9)
 1 21 (29.6) 53 (30.1) 74 (29.9)
 2 28 (39.5) 43 (24.4) 71 (28.7)
 3 6 (8.5) 15 (8.5) 21 (8.5)
 4 2 (2.8) 5 (2.8) 7 (2.8) 0.103
CD4 count at HIV diagnosisb
 < 350 40 (56.3) 89 (50.6) 129 (52.2)
 ≥ 350 25 (35.2) 42 (23.9) 67 (27.1)
 Missing 6 (8.5) 45 (25.6) 51 (20.7) 0.374
 Median CD4 count at HIV diagnosis (IQR)b 294 (121–419) 249 (150–393) 261.5 (146–403.5)
 HIV suppression rates 64 (90.1) 147 (83.5) 211 (85.4)
 Missing 7 (9.9) 28 (15.9) 35 (14.2) 0.627

HTN Hypertension, DM Diabetes mellitus type 2, DMHTN dual diagnosis of HTN and Diabetes Mellitus type 2, NCD non-communicable disease which implies either DM or HTN or both in this case, SD standard deviation of the mean

aCharacteristics are described as n (%) where n is number of participants with the characteristic and % is percentage of the study population with the given characteristic

bCells/µL

Bold p values indicated statitistical significance